Covered recipient · General Payments record
ELIZABETH A FASY
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
General Payments · PY2018–2024
$3,799.15
- Reported across 111 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $601.15 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| DEXCOM, INC. | $191.28 | 5 |
| Amgen Inc. | $149.39 | 2 |
| Novo Nordisk AS | $137.20 | 2 |
| Abbott Laboratories | $38.79 | 2 |
| Corcept Therapeutics | $24.08 | 1 |
| Insulet Corporation | $21.92 | 1 |
| Ascensia Diabetes Care US Inc. | $20.76 | 1 |
| SANOFI-AVENTIS U.S. LLC | $17.73 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $17.19 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124988095 | CMS |
| Abbott Laboratories | $21.60 | 11/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124988091 | CMS |
| Amgen Inc. | $20.45 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111572790 | CMS |
| Amgen Inc. | $128.94 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111572792 | CMS |
| Ascensia Diabetes Care Us Inc. | $20.76 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089087632 | CMS |
| Corcept Therapeutics | $24.08 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117784562 | CMS |
| Dexcom, Inc. | $23.38 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153298365 | CMS |
| Dexcom, Inc. | $23.61 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153298367 | CMS |
| Dexcom, Inc. | $5.62 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153298369 | CMS |
| Dexcom, Inc. | $23.58 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153298371 | CMS |
| Dexcom, Inc. | $115.09 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153298373 | CMS |
| Insulet Corporation | $21.92 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116797521 | CMS |
| Novo Nordisk Inc | $23.62 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097504815 | CMS |
| Novo Nordisk Inc | $113.58 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097186802 | CMS |
| SANOFI-AVENTIS U.S. LLC | $17.73 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139940359 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.